On the prediction of Hodgkin lymphoma treatment response

Clinical and Translational Oncology

Volumn 17, Issue 8, 2015, Pages 612-619

  deAndres Galiana E J ^a   Fernandez Martinez J L ^a   Luaces, O ^a   del Coz, J J ^a   Fernandez R ^b   Solano, J ^c   Nogues E A ^c   Zanabilli, Y ^d   Alonso, J M ^e   Payer, A R ^c   Vicente, J M ^f   Medina, J ^d   Taboada, F ^g   Vargas, M ^h   Alarcon C ^d   Moran M ^d   Gonzalez Ordonez A ^d   Palicio, M A ^h   Ortiz, S ^h   Chamorro, C ⁱ   Gonzalez, S ^j   Gonzalez Rodriguez A P ^c   more..

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL SAN AGUSTÍN   (Spain)

^e HOSPITAL VALLE DEL NALÓN   (Spain)

^f Hematology Department Hospital de Mieres   (Spain)

^g Hospital Cangas de Narcea   (Spain)

^h Internal Medicine Department   (Spain)

ⁱ Hospital de Arriondas   (Spain)

^j DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

more..

Author keywords

Alanine aminotransferase (ALT); Alkaline phosphatase (ALP); Hodgkin lymphoma; Machine learning; Serum ferritin (SF); Treatment response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BLEOMYCIN; C REACTIVE PROTEIN; DACARBAZINE; DOXORUBICIN; FERRITIN; IMMUNOGLOBULIN; KI 67 ANTIGEN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CAUCASIAN; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HODGKIN DISEASE; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VERY ELDERLY; CANCER STAGING; INCIDENCE; INFLAMMATION; IRON OVERLOAD; LIVER DISEASES; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INCIDENCE; INFLAMMATION; IRON OVERLOAD; LIVER DISEASES; MACHINE LEARNING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 84937970941     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1285-z     Document Type: Article

References (28)

1. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, Bosch-Princep R, Reverter-Branchat G, Jaen-Martinez J, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin’s lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005;46(11):1581–91.
2. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al. Prognostic impact of tumour-infiltrating th2 and regulatory t cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27(1):31–9.
3. Hasenclever D, Diehl V, Armitage JO, Assouline D, Björkholm M, Brusamolino E, et al. A prognostic score for advanced Hodgkin’s disease. New Eng J Med. 1998;339(21):1506–14.
4. Friedman S, Henry-Amar M, Cosset JM, Carde P, Hayat M, Dupouy N, et al. Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin’s disease. J Clin Oncol. 1988;6(4):596–602.
5. Mauch P, Larson D, Osteen R, Silver B, Yeap B, Canellos G, et al. Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol. 1990;8(2):257–65.
6. Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am. 2008;46(2):213–23.
7. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim pet in abvd-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683–90.
8. Smolewski P, Robak T, Krykowski E, Blasinska-Morawiec M, Niewiadomska H, Pluzanska A, et al. Prognostic factors in Hodgkin’s disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6(3):1150–60.
9. Zander T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin’s lymphoma. Ann Oncol. 2002;13(Suppl 1):67–74.
10. Josting A. Prognostic factors in Hodgkin lymphoma. Expert Rev Hematol. 2010;3(5):583–92.
11. Provencio M, Espana P, Millan I, Yebra M, Sanchez AC, de la Torre A, et al. Prognostic factors in Hodgkin’s disease. Leuk Lymphoma. 2004;45(6):1133–9.
12. Ong DST, Wang L, Zhu Y, Ho B, Ding JL. The response of ferritin to lps and acute phase of pseudomonas infection. J Endotoxin Res. 2005;11(5):267–80.
13. Cheson BD. The international harmonization project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841–54.
14. Saligan L, Fernández-Martínez JL, deAndrés-Galiana EJ, Sonis S. Supervised classification by filter methods and recursive feature elimination predicts risk of radiotherapy-related fatigue in patients with prostate cancer. Cancer Inform. 2014;13(141–152):12.
15. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, et al. Plasma epstein-barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin’s lymphoma. Clin Cancer Res. 2006;12(2):460–4.
16. Bezwoda WR, Derman DP, Bothwell TH, Baynes R, Hesdorffer C, MacPhail AP. Serum ferritin and Hodgkin’s disease. Scand J Haematol. 1985;35:505–10.
17. Dörner MH, Abel U, Fritze D, Manke HG, Drings P. Serum ferritin in relation to the course of Hodgkin’s disease. Cancer. 1983;52:2308–12.
18. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, et al. Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol. 2010;28(15):2538–43.
19. Hohaus S, Giachelia M, Cuccaro A, Voso MT, Leone G. Iron in Hodgkin’s lymphoma. Crit Rev Oncog. 2013;18(5):463–9.
20. Aulbert E, Steffens O. Serum ferritin–a tumor marker in malignant lym-phomas? Onkologie. 1990;13(2):102–8.
21. Yoh KA, Lee HS, Park LC, Lee EM, Shin SH, Park DJ, et al. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14(1):43–9.
22. Kaplan MM. Alanine aminotransferase levels: what’s normal? Ann Intern Med. 2002;137(1):49–51.
23. Kittivorapart J, Chinthammitr Y. Incidence and risk factors of bone marrow involvement by non-Hodgkin lymphoma. J Med Assoc Thai. 2011;94(Suppl 1):S239–45.
24. Jamakovic M, Baljic R. Significance of copper level in serum and routine laboratory parameters in estimation of outspreading of Hodgkin’s lymphoma. Med Arch. 2013;67(3):185–7.
25. 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma. 2014;55(10):2349–55.
26. Brensilver HL, Kaplan MM. Significance of elevated liver alkaline phosphatase in serum. Gastroenterology. 1975;68(6):1556–62.
27. Brinckmeyer LM, Skovsgaard T, Thiede T, Vesterager L, Nissen NI. The liver in Hodgkin’s disease. Clinico-pathological relations. Eur J Cancer Clin Oncol. 1982;18(5):421–8.
28. Cunha BA. Fever of unknown origin (FUO): diagnostic importance of serum ferritin levels. Scand J Infect Dis. 2007;39(6–7):651–2.